US2009259027A1PendingUtilityA1

Human GM-CSF antibodies

61
Assignee: RENNER CHRISTOPHPriority: Feb 13, 2002Filed: May 29, 2008Published: Oct 15, 2009
Est. expiryFeb 13, 2022(expired)· nominal 20-yr term from priority
C07K 2317/56C07K 16/243C07K 2319/00C07K 2319/75C07K 2317/92C07K 14/525C07K 2317/73C07K 2317/732A61P 29/00C07K 2317/734C07K 2317/24C07K 16/3038C07K 16/40C07K 16/2878C07K 16/30C07K 2319/33C07K 2319/30
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosis factor. Expression vectors adapted for production of the antibodies, as well as methods for manufacturing these, are also disclosed.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . An isolated, humanized antibody which specifically binds to granulocyte, macrophage, colony stimulating factor (GM-CSF). 
     
     
         18 . The isolated, humanized antibody of  claim 17 , wherein a complementary determining region (CDR) thereof is of non-human origin. 
     
     
         19 . The isolated humanized antibody of  claim 18 , wherein said isolated humanized antibody comprises a light chain, complementary determining region (CDR) of murine origin. 
     
     
         20 . The isolated humanized antibody of  claim 18 , wherein said isolated humanized antibody comprises a heavy chain, complementary determining region (CDR) of murine origin. 
     
     
         21 . The isolated humanized antibody of  claim 18 , wherein said isolated humanized antibody comprises both a light chain, complementary determining region (CDR) of murine origin, and a heavy chain, complementary determining region (CDR) of murine origin. 
     
     
         22 . The isolated humanized antibody of claim  5 , wherein both of said CDRs have an amino acid sequence identical to the CDR sequences of murine 19/2 antibody.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.